Xenon Pharmaceuticals Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
XENE$40.45+3.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(Expressed in thousands of U.S. dollars except share amounts)
| September 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $82,560 | $199,163 |
| Marketable securities (note 5) | 868,238 | 349,723 |
| Other receivables | 1,169 | 1,371 |
| Prepaid expenses and other current assets | 8,098 | 10,392 |
| Total current assets | 960,065 | 560,649 |
| Marketable securities, non-current (note 5) | 202,680 | 37,152 |
| Operating lease right-of-use asset, net (note 6) | 5,055 | 6,626 |
| Property, plant and equipment, net | 7,461 | 8,721 |
| Deferred tax assets | 15,459 | 12,864 |
| Prepaid expenses and other assets, non-current | 9,155 | 7,151 |
| Total assets | $1,199,875 | $633,163 |
| Liabilities and shareholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities (note 7) | $44,154 | $40,260 |
| Operating lease liability (note 6) | 1,150 | 1,532 |
| Total current liabilities | 45,304 | 41,792 |
| Operating lease liability, non-current (note 6) | 4,859 | 6,412 |
| Other non-current liabilities | 3,330 | 3,199 |
| Total liabilities | 53,493 | 51,403 |
| Shareholders’ equity: | ||
| Common shares, without par value; unlimited shares authorized; issued and outstanding: 98,275,278 (December 31, 2025 - 80,010,790) (note 8) | 2,492,998 | 1,598,571 |
| Additional paid-in capital | 227,290 | 228,234 |
| Accumulated deficit | (1,568,853) | (1,245,380) |
| Accumulated other comprehensive income (loss) | (5,053) | 335 |
| Total shareholders’ equity | 1,146,382 | 581,760 |
| Total liabilities and shareholders’ equity | $1,199,875 | $633,163 |
| Commitments and contingencies (note 11) | ||
-3-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.